| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|
| ||||||||||||||||||||||||||||||||
1 Andrus Gerontology Center, University of Southern California, Los Angeles.
2 School of Aging Studies, University of South Florida, Tampa.
3 Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver.
4 Division of Geriatrics, University of California, Los Angeles, School of Medicine.
Address correspondence to Eileen M. Crimmins, PhD, Andrus Gerontology Center, University of Southern California, 3715 McClintock Avenue, MC 0191, Los Angeles, CA 90089-0191. E-mail: crimmin{at}usc.edu
|
A |
|---|
|
|
|---|
Methods. Changes in the prevalence of clinically-defined, high risk for 10 biological markers were assessed in respondents age 65 years and older from National Health and Nutrition Examination Surveys (NHANES) III (19881994) and IV (19992000).
Results. Some changes in prevalence of high-risk values of biological markers indicate improved health among older adults in the 1990s: a 6% reduction in the prevalence of high-risk total cholesterol (p <.001) and a 7% reduction in the prevalence of high-risk homocysteine (p <.001). Other changes indicate worsening health: a 9% increase in the prevalence of high-risk systolic blood pressure (p <.01), a 10% increase in obesity (p <.001), and an 8% increase in the prevalence of high-risk C-reactive protein (p <.001). These changes remained significant after adjusting for age, sex, and education. Results of logistic regressions indicate that changes in the frequency of medication usage, medication efficacy, prevalence of chronic disease, and diet explained some of these changes.
Conclusions. Changes in the prevalence of high-risk values of biological markers in the 1990s are mixed. Greater use and effectiveness of lipid-lowering medication has contributed to the reduction in percentage of the population with high-risk lipid levels, and folate supplementation accounted for a decline in the percentage with high-risk homocysteine. However, increases in the percentage with high-risk systolic blood pressure occurred despite an increase in the use of antihypertensive medications, in part because of the limited ability of antihypertensive medications to bring blood pressure below high-risk levels.
Most studies examining trends in the health of older adults have focused on self-reports of health that can be affected by circumstances other than the intrinsic health of the individual (7,8). For instance, self-reports of conditions and diseases are subject to variations in knowledge, access to health care, and disease diagnosis. Disability measures can be confounded by role expectations and living environments (9,10).
In contrast, the physiological status that underlies disability, loss of functioning, disease, and mortality can be more directly measured through biological indicators of risk. Trends in these biological markers should be a good indicator of trends in the innate health status of the older population as all of these markers have been linked to higher mortality, poorer physical and cognitive functioning, and more heart disease (1116).
Past research on trends in biological risk markers has focused on cardiovascular risk factors, namely blood pressure, serum cholesterol levels, and relative weight (1719). From the 1960s through the early 1990s, decreases in hypertension were fueled by increased diagnosis and treatment of blood pressure problems (17,20). However, there is some evidence that improvement in blood pressure may have stopped and that blood pressure may have actually increased through the 1990s (21). Cholesterol appears to have decreased steadily from the 1960s through 2000 (22). One of the most adverse health trends in recent decades has been the increase in weight and obesity (23). Several other markers, such as triglycerides, glycated hemoglobin, C-reactive protein (CRP), and homocysteine level, are increasingly considered clinically relevant and change over time in these markers also requires attention. The intent of this article is to examine changes in the prevalence of high-risk values for indicators of physiological functioning in older Americans through the 1990s and to explore reasons for these observed changes.
| METHODS |
|---|
|
|
|---|
Measures
We examined change across the two studies in the percentage of the population with measured values above (or below) clinically defined "high risk" levels for 10 biological markers: diastolic blood pressure, systolic blood pressure, high-density lipoprotein (HDL) cholesterol, fasting low-density lipoprotein (LDL) cholesterol, total cholesterol, glycated hemoglobin, body mass index (BMI), fasting triglycerides, CRP, and homocysteine. Clinical cut points used to define high-risk levels are shown in Table 1. For all variables, at least 87% of those eligible to provide data did so at both dates. Measures of LDL cholesterol and triglycerides were available for the participants in the morning sample fasting at least 6 hours (about 40% of the total laboratory sample), and measures of homocysteine were only available for the second half of NHANES III (19911994). For these reasons, these three indicators have data for a smaller number of respondents.
|
Measured values of biological markers were used to identify individuals with high-risk levels of each indicator, regardless of medication use status. Thus, persons on medication whose measured levels were outside the risk range were not considered to be at risk. Subsequent analyses examined the changing prevalence of medication usage relative to measured risk. Self-report data were used to examine age, gender, education, disease diagnosis, and medication prescription.
Analysis
First, we examined change across the surveys in the percentage with high-risk values. For each biomarker, we then used logistic regression to examine the relative odds of being at high risk in the NHANES IV sample versus the NHANES III sample. Regression models examined the relative odds of being high-risk after controlling for changes in age and sex of the population (Model 1) and educational level (Model 2). Because weight increased markedly between the two surveys, Model 3 also controlled for BMI. A final set of analyses explored changes in factors likely to affect change in individual biomarkers, including diagnosis and medication use, prevalence of chronic disease, and the level of serum folate.
| RESULTS |
|---|
|
|
|---|
Explanations for Changes in Percentage of Population With High-Risk Values of Biological Markers
Table 2 presents results from regression models testing the robustness of the observed differences in prevalence of high risk to controls for change in population composition. Model 1 indicates the odds ratios for being in the high-risk group in NHANES IV versus NHANES III adjusted for age and sex. Generally, the results are the same as those in Table 1, indicating that changes in age and in sex composition, or both, do not explain observed changes over time. The odds for high-risk levels of systolic blood pressure were 26% higher, the odds for high-risk BMI were 43% higher, and the odds for high-risk CRP were 68% higher for the NHANES IV sample than for the NHANES III sample. However, the odds of having high-risk levels of LDL and total cholesterol were 28% and 35% lower, respectively, and the odds of having a high-risk level of homocysteine were 40% lower. The odds of having high-risk diastolic blood pressure, HDL cholesterol, glycated hemoglobin, and fasting triglycerides did not change significantly.
|
Explanations for Changes in Specific Markers
To further investigate the causes for these changes, we assessed changes in related factors. For blood pressure and cholesterol, we examined changes in diagnosis, medication prescription, and use and effectiveness of medication. To do this, we divided the sample by diagnosis, use of medication, and measured risk group. For CRP, we examined changes in the prevalence of concurrent disease. For homocysteine, we examined changes in level of serum folate.
Systolic blood pressure.-- Self-report of physician diagnosis of high blood pressure increased during the 1990s, with 41% of older adults reporting that they had been diagnosed with high blood pressure in NHANES III (46% in NHANES IV). However, the use of medication to control hypertension in the older population also increased during the 1990s, from 35% in NHANES III to 43% in NHANES IV. If we used an alternative approach to defining high-risk blood pressure that included those taking medication as well as those with measured high-risk systolic blood pressure, the increase in the presence of high-risk blood pressure between NHANES III and NHANES IV would have been even greater, from 59% to 70%.
Among those persons who reported having been diagnosed with high blood pressure, almost all (90%) had been told to take medication in each survey. Taking blood pressure medication does not necessarily reduce an individual's blood pressure below the risk level; among those taking medication, 56% in NHANES III and 60% in NHANES IV (19.4% and 25.1% of the total samples) had high measured systolic blood pressure. Another reason for the rise in measured systolic blood pressure is the increase in undiagnosed high blood pressure, in which participants measured at-risk did not report prior diagnosis (17% in NHANES III to 22% in NHANES IV). Thus, despite the increase in treatment, an increase in undiagnosed high blood pressure and diagnosed, but inadequately controlled, hypertension are factors in the growing prevalence of high-risk systolic blood pressure.
Cholesterol.-- Although we observed a decline in measured high-risk LDL and total cholesterol, the percentage reporting that they had been diagnosed with high cholesterol increased (31% in NHANES III vs 45% in NHANES IV). There was also an increase in the use of medication to control cholesterol, from 20% to 35%. Medication prescription among those diagnosed with high cholesterol increased markedly during the 1990s (from 33% in NHANES III to 62% in NHANES IV). In addition, the effectiveness of medications available to treat high cholesterol increased (33). In NHANES III, 40% of those taking medication still had high-risk levels of cholesterol; this figure fell to only 21% in NHANES IV. Thus, increases in cholesterol testing and diagnosis, as well as increased use and efficacy of medications, may have contributed to the observed decrease in high-risk total cholesterol.
C-reactive protein.-- The increase in CRP observed here was paralleled by an increase in BMI (Table 2, Models 2 and 3). Controlling for BMI suggests that, without the increase in weight, the odds of high-risk CRP in NHANES IV versus NHANES III would have been 59% higher, instead of 70%. Higher CRP levels in NHANES IV may also be associated with the increased prevalence of chronic diseases in the later survey period. Controlling for the change in prevalence of seven chronic conditions related to inflammation (hypertension, diabetes, chronic heart failure, heart attack, asthma, chronic bronchitis, and arthritis) reduced the odds ratio (OR) for the indicator of change in high-risk CRP by 0.12 (results not shown), suggesting that some of the observed increase in CRP was related to the concurrent increasing prevalence of chronic conditions.
Homocysteine.-- We considered whether the decreasing prevalence of high-risk homocysteine might be the result of changes in folate supplementation. Higher levels of serum folate led to lower levels of homocysteine (34), and folate consumption in the population increased after 1998 because of regulated folate supplementation of cereals and flours to prevent neural tube defects in fetuses (35). Although this policy was oriented toward improving pregnancy outcomes, it also resulted in improved dietary intake of folate among elderly persons. The mean level of serum folate in the older population increased from 9.8 ng/ml in NHANES III to 20.9 ng/ml in NHANES IV. These increasing levels of serum folate appear to completely explain the decrease in high-risk homocysteine levels between the two surveys, as addition of serum folate to Model 3 in Table 2 resulted in an insignificant OR for the indicator of change in homocysteine (OR = 1.14, results not shown).
| DISCUSSION |
|---|
|
|
|---|
In contrast to these patterns of increasing risk, prevalence of high-risk cholesterol showed considerable improvement during the 1990s. This appears to partially result from the dramatic increase in the use of more effective lipid-lowering medications. Another notable health improvement during the 1990s was the reduction in high-risk homocysteinea change that appears to have been accomplished through public health efforts that led to elevations in serum folate levels in the older U.S. population.
Conclusion
We found mixed patterns of change in the prevalence of high-risk levels of various clinically relevant biomarkers in older Americans through the 1990s: increasing prevalence of high-risk levels for some measures, but decreasing levels for others. Overall, the data suggest that the prevalence of high-risk levels would have risen more without the increased use of medications.
|
A |
|---|
|
|
|---|
Preliminary results were presented at the Annual Meeting of the Population Association of America, Boston, Massachusetts, April 2, 2004.
|
F |
|---|
|
|
|---|
Received September 24, 2004
Accepted December 20, 2004
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. G. Parker and M. Thorslund Health Trends in the Elderly Population: Getting Better and Getting Worse Gerontologist, April 1, 2007; 47(2): 150 - 158. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||
| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|